{
    "2019-09-01": [
        [
            {
                "time": "",
                "original_text": "复星医药董事长陈启宇：抗癌创新药降价是必经之路",
                "features": {
                    "keywords": [
                        "复星医药",
                        "抗癌创新药",
                        "降价"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "连续8个月\"无脑\"买入！北向资金持仓生物医药市值增长78%，这些个股最青睐",
                "features": {
                    "keywords": [
                        "北向资金",
                        "生物医药",
                        "市值增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "证金、汇金、QFII最新持股曝光 他们最爱哪些股？",
                "features": {
                    "keywords": [
                        "证金",
                        "汇金",
                        "QFII",
                        "持股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中国债券史上首例！上市公司折价购买自己发的债券，实现负成本融资！",
                "features": {
                    "keywords": [
                        "债券",
                        "折价购买",
                        "负成本融资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "光大医药 | 中报总结：集采后的第一份答卷，影响如何，未来在哪？",
                "features": {
                    "keywords": [
                        "光大医药",
                        "中报",
                        "集采"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-09-09",
                "original_text": "[民生医药|周报]09/09：政策影响钝化，二线公司关注度提升",
                "features": {
                    "keywords": [
                        "民生医药",
                        "政策影响",
                        "二线公司",
                        "关注度提升"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "创新药风口猛刮！恒瑞半年营收100亿 中国生物制药125亿",
                "features": {
                    "keywords": [
                        "创新药",
                        "恒瑞",
                        "营收",
                        "中国生物制药"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "集采扩面方案出台，多家企业中标有望成为未来的“新常态”",
                "features": {
                    "keywords": [
                        "集采",
                        "扩面方案",
                        "中标",
                        "新常态"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药上半年净利润24.12亿元，研发费用上涨近5成",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "净利润",
                        "研发费用",
                        "上涨"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}